Presented by:

Sponsored by:

Now available on demand. Sign up to view

Making a name in cancer immunotherapy


Originally aired; June 13, 2017

The successful approach of cancer immunotherapy—using the body’s own immune system to fight cancer—continues to push boundaries, provide new avenues for research and ultimately a new breed of candidates and technologies for the treatment of patients.

This webcast will bring a number of cancer immunotherapy companies working in the field together to present their technologies and explain how they are advancing progress within immuno-oncology. The approaches and technologies covered within the webcast will include: Bioclonics, differentiated bispecific antibody therapeutics; LAMP-Vax, a unique immunotherapy platform creating DNA-based vaccines; targeted radioimmunotherapies, antibodies delivering radioisotopes and a precision engineering platform IsoCode for predictive cell response. 

The webcast will conclude with a live roundtable discussion and a Q&A session with the speakers for you the audience to put your own questions to them.

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

Webcast sponsors retain sole responsibility for content.

Sia Anagnostou
Senior Director of Corporate Development
Immunomic Therapeutics, Inc.
View Biography
Prof. Ton Logtenberg
Founder and Chief Executive Officer
Merus N.V.
View Biography
Sean Mackay
Co-Founder, Chief Executive Officer and Director
View Biography
Dr. Mark Berger
Chief Medical Officer
Actinium Pharmaceuticals, Inc.
View Biography
Moderator: Raveena Bhambra
BioPharma Dealmakers

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)